News | August 06, 2013

Edwards Receives IDE for U.S. Clinical Trial of Sapien 3 Transcatheter Valve

Edwards Sapien 3 Transcatheter Aortic Hear Valve Clinical Trial

August 6, 2013 — Edwards Lifesciences received conditional investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate a clinical trial of its Edwards Sapien 3 transcatheter aortic heart valve and accessories.

The trial will study the Sapien 3 valve in the treatment of high-risk and inoperable patients with severe symptomatic aortic stenosis. It will enroll up to 500 patients treated with one of three delivery techniques: the transfemoral approach through an incision in the leg, the transapical route between the ribs, or the transaortic approach through a small incision in the chest and aorta. Edwards anticipates the trial will have a one-year composite endpoint compared to previous Sapien valves.

"We're very excited to have the opportunity to initiate a U.S. study of the Sapien 3 valve. This valve builds on the Sapien platform and provides new features designed to benefit patients and enhance ease of use, such as a lower profile, a fabric cuff intended to reduce paravalvular leak and new delivery systems," said Larry L. Wood, corporate vice president, transcatheter heart valves. "We appreciate the FDA's efforts to allow initiation of this trial in a timely way, providing U.S. patients with access to our most advanced transcatheter system."

The Edwards Sapien 3 valve is an investigational device and is not available commercially in any country.

For more information: www.edwards.com

Related Content

BioTrace Medical's Tempo Lead Shows Stability and Safety in Real-World Performance
News | Leads Implantable Devices| June 20, 2017
BioTrace Medical Inc. announced that the company’s Tempo Temporary Pacing Lead was featured in an oral presentation and...
heart valve regurgitation seen on an echocardiogram, cardiac ultrasound, from ASE study
News | Cardiovascular Ultrasound| June 16, 2017
June 15, 2017 – While much attention has been focused on ways to lower heart disease-related injuries and deaths, the
Mitral Valve regurgitation showed on an echocardiogram, cardiac ultrasound

Mitral valve regurgitation showed on an echocardiogram. Image from Toshiba.

News | Heart Valve Technology| June 15, 2017
June 15, 2017 — 4C Medical Technologies Inc., a developer of minimally invasive therapies for structural heart diseas
Sponsored Content | Videos | Heart Valve Technology| June 14, 2017
A discussion with Rebecca Hahn, M.D., FASE, director of interventional echocardiography and professor of medicine at
FDA clears Claret Medical Sentinel embolic protection device for TAVR
Feature | Heart Valve Technology| June 09, 2017
June 5, 2017 – The U.S.
Sapien 3 valve for VIV (valve in valve) procedures cleared by FDA
Feature | Heart Valve Technology| June 06, 2017 | Dave Fornell
The U.S. Food and Drug Administration (FDA) has granted market clearance for aortic and mitral valve-in-valve...
LivaNova Announces Positive Data for Perceval Sutureless Valve at AATS 2017
News | Heart Valve Technology| May 31, 2017
LivaNova PLC recently announced the presentation of data from multiple studies demonstrating the safety and...
News | Guidewires| May 30, 2017
A Canadian cardiologist has published a report in the journal Eurointervention describing how he used a Canadian-...
Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve
News | Heart Valve Technology| May 24, 2017
May 24, 2017 — Late-breaking data presented at EuroPCR 2017 demonstrating excellent clinical outcomes for...
Overlay Init